Latest Ratios: P/E Ratio -46.8x · EV/EBITDA N/A · ROE -8.1%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.9B | $2.7B | $2.0B | $2.1B | $2.7B | $5.1B | $3.8B | — | — | — |
| Enterprise Value | $3.9B | $2.7B | $1.9B | $1.8B | $2.7B | $4.7B | $3.8B | — | — | — |
| P/E Ratio → | -46.81 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 27.88 | 19.62 | 32.14 | 5.56 | 44.95 | 98.73 | 158970.84 | — | — | — |
| P/B Ratio | 3.03 | 2.21 | 2.78 | 2.14 | 3.73 | 6.19 | 15.54 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 121.56 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 19.61 | 30.24 | 4.86 | 44.07 | 90.77 | 156698.88 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.0% | 84.0% | -478.7% | 100.0% | -411.5% | -347.8% | -429812.5% | -303338.9% | — | — |
| Operating Margin | -274.6% | -274.6% | -654.3% | -46.7% | -555.6% | -757.0% | -553166.7% | -417522.2% | — | — |
| Net Profit Margin | -57.2% | -57.2% | -593.1% | -35.1% | -474.5% | -714.9% | -810800.0% | -435144.4% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.1% | -8.1% | -43.9% | -15.5% | -37.1% | -69.1% | -112.3% | -66.7% | -177.5% | — |
| ROA | -6.2% | -6.2% | -29.4% | -9.5% | -20.5% | -38.5% | -64.0% | -48.5% | -136.1% | -363.4% |
| ROIC | -31.1% | -31.1% | -46.8% | -18.9% | -46.4% | -97.2% | -69.6% | -136.6% | — | — |
| ROCE | -33.3% | -33.3% | -38.2% | -14.9% | -28.5% | -48.7% | -55.7% | -56.0% | -66.6% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.24 | 0.22 | 0.18 | 0.24 | 0.18 | 0.44 | 0.31 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.00 | -0.16 | -0.27 | -0.07 | -0.50 | -0.22 | -0.06 | -1.09 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -0.83 | -0.83 | — | — | — | — | — | -401.89 | — | — |
Net cash position: cash ($295M) exceeds total debt ($294M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.09 | 13.09 | 4.82 | 5.89 | 4.89 | 5.96 | 3.01 | 3.24 | 5.79 | 0.31 |
| Quick Ratio | 13.09 | 13.09 | 4.82 | 5.89 | 4.89 | 5.96 | 3.01 | 3.24 | 5.79 | 0.31 |
| Cash Ratio | 12.85 | 12.85 | 4.67 | 5.79 | 4.82 | 4.52 | 2.93 | 3.15 | 5.72 | 0.29 |
| Asset Turnover | — | 0.09 | 0.06 | 0.26 | 0.05 | 0.04 | 0.00 | 0.00 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | 2112.11 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $99M | $82M | $77M | $70M | $64M | $47M | $51M | $35M | $13M |
Clinical Milestone Revenue Volatility
As reported in financial statements, BEAM trades at a 25.59x price-to-sales multiple, a valuation that appears disconnected from the company's lack of recurring product revenue and its reliance on highly volatile, milestone-driven collaboration income that does not provide a reliable basis for long-term earnings growth projections.
The current P/S multiple suggests that investors are pricing in the potential of the base-editing platform rather than current financial performance. This valuation premium warrants caution, as it assumes successful clinical outcomes and future commercialization that remain highly uncertain compared to more mature peers.
Based on recent SEC filings, BEAM's ROIC has trended into negative territory, reaching -7.1% in 2026Q1, which indicates that the company is currently destroying shareholder value as it deploys capital into R&D programs that have yet to demonstrate a path toward sustainable, positive economic returns.
The consistent negative ROIC reflects the high capital intensity required to sustain clinical-stage biotechnology operations. Investors should monitor whether the company can improve these returns as it narrows its pipeline focus, though current trends suggest that capital efficiency remains a significant hurdle for the business model.
According to the provided quarterly data, the company's current ratio has fluctuated significantly, settling at 16.99 in 2026Q1, yet this metric masks the underlying reality that the firm's cash reserves are being rapidly depleted by persistent operating losses and high R&D expenditures.
While the high current ratio might appear to suggest a strong liquidity position, it is largely a function of the company's cash-heavy balance sheet relative to its current liabilities. The lack of recurring revenue means this liquidity is finite, and the company remains vulnerable to capital market conditions as it approaches future funding requirements.
As evidenced by the erratic swings in net margins, investors frequently misapply traditional profitability metrics to BEAM, failing to recognize that these figures are distorted by non-recurring milestone payments rather than reflecting the underlying operational health of the company's gene-editing platform.
Using net margin or P/E ratios to evaluate a pre-revenue biotech firm is fundamentally flawed, as these metrics obscure the true cash-burn rate and the timing of collaboration revenue. Analysts should instead focus on cash runway and clinical milestone progress to better assess the company's long-term viability.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BEAM stock.
Beam Therapeutics Inc.'s current P/E ratio is -46.8x. This places it at the 50th percentile of its historical range.
Beam Therapeutics Inc.'s return on equity (ROE) is -8.1%. The historical average is -66.3%.
Based on historical data, Beam Therapeutics Inc. is trading at a P/E of -46.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Beam Therapeutics Inc. has 84.0% gross margin and -274.6% operating margin.